Sharon Hesterlee's Blog – July 2010 Archive (1)
Rock, meet Hard Place
The news that GSK is not pursuing a phase III study for skipping exon 51 here in the US has certainly come as a blow. It seems that the FDA would like to see longer term toxicology data before approving the 48 week human study. Meanwhile, almost every European family with DMD will have access to the phase III study. It seems obvious that the FDA is being blindly obstructionist and GSK is showing its true stripes as money-sucking big pharma company that is going to choose the path of least…
ContinueAdded by Sharon Hesterlee on July 6, 2010 at 4:00pm — 24 Comments
Latest Blog Posts
Most Popular Blog Posts
- GSK and Prosensa announce primary endpoint not met in Phase III study of drisapersen
- Positive Phase 1 trial results for SMT C1100 in Duchenne (Summit PLC)
- Now is the time for strength.
- Without Endings There Are No Beginnings…
- Parent Project Muscular Dystrophy awards $50,000 to Dr. Toshifumi Yokota for multi-exon skipping project
- Drug Development Prospects for Duchenne: The Pipeline is rich and deep, with lots of forward momentum
- World Muscle Society Congress: Next Generation Exon-Skipping & Clinical Trial Updates
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
